CP-101606 Pfizer Inc.

P L Chazot

Home/Archive/PubMed

PubMed · 11249721

CP-101606 Pfizer Inc.

P L Chazot

View original source ↗Export metadata ↓

Abstract

CP-101606 is a potent, selective NMDA receptor (NR2B subunit) antagonist under development by Pfizer for its potential as a neuroprotectant in head injury and neurodegenerative disease. It is in phase II trials in the US and in phase I in Japan for the potential treatment of head injury [267139], [320737], [378812]. As of March 2000, CP-101606 had completed US phase I trials successfully and was well tolerated with a good safety profile. Results of an open-label study in patients treated with CP-101606 (24 to 72 h infusion) following severe head trauma showed that 80% of patients had good recovery at the 3-month follow-up stage [360864]. In August 2000, Merrill Lynch predicted that the phase II trials program could be complete by the end of 2000 with the possibility of a filing based on its results if positive [379892]. The drug lacks the amnesic side effects of other NMDA receptor antagonists and it has no effects on long-term potentiation (LTP) [347642]. According to presenters at the 1999 Society for Neuroscience meeting, this may result from a novel activity-dependent or NR2B-selective mechanism of action [345079]. It is thought to act by inhibiting the damaging influx of Ca2+ across neuronal cell membranes following glutamate release triggered by tissue injury, e.g., stroke [300847]. CP-101606 prevents glutamate-induced toxicity in cultured hippocampal neurons when given during or immediately after glutamate perfusion, (IC50 = 11 and 35 nM, respectively). In contrast, CP-101606 does not protect against glutamate-induced neurotoxicity in cultured cerebellar neurons, up to a dose of 10 microM. These results are consistent with CP-101606 being a potent NMDA antagonist, selective for the type of NMDA receptor associated with the hippocampus [195435]. CP-101606 is a single isomer analog of CP-98113 (Pfizer Inc) [254010]. CP-101581 (Pfizer Inc) is an isomer of CP-101606 [254010]. In December 1998, Morgan Stanley Dean Witter predicted sales of US $5 million in 2001, rising to US $80 million by 2005 [315350].

Explore related subjects

Animals Clinical Trials as Topic Contraindications Drugs, Investigational Excitatory Amino Acid Antagonists Humans Neuroprotective Agents Piperidines Receptors, N-Methyl-D-Aspartate Structure-Activity Relationship Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

P L Chazot. 2000. CP-101606 Pfizer Inc.. https://pubmed.ncbi.nlm.nih.gov/11249721/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Protocol for Detecting and Sequencing Chikungunya Virus from Field-Collected Mosquitoes.

Arboviral diseases represent a major public health challenge, especially in tropical regions where environmental conditions may favor the proliferation and spread of mosquito vectors. Thus, early and accurate detection of chikungunya virus (CHIKV) in mosquito populations can be a valuable tool for effective surveillance of circulating variants and for identifying new viral introductions. Given the challenges of detecting arboviruses in field-captured mosquitoes, we describe an integrated workflow for CHIKV molecular detection and whole-genome sequencing. This protocol includes mosquito homogenization using a bead-based mechanical disruptor, RNA extraction using TRIzol reagent with minor modifications, molecular screening using CHIKV-specific RT-qPCR, and whole-genome amplification followed by sequencing on Illumina platforms. Despite the protocol being optimized for individual mosquitoes, it results in high-quality RNA suitable for both entomological surveillance and genomic analysis. As this protocol allows recovery of complete CHIKV genomes from mosquito specimens, it can serve as a basis for genomic epidemiology studies, enabling monitoring of viral diversity and lineage dynamics, and facilitating early detection of emerging variants to support timely and targeted public health interventions in endemic and at-risk regions.

Animals↗

PubMed2027

Genomic Profiling of Chromatin State Using CUT&Tag.

Alterations in chromatin state, mediated through histone modifications and the incorporation of histone variants, are fundamental to establishing transcriptional networks and cell identity. Recent advances in low-input epigenome profiling methods, such as CUT&Tag and CUT&RUN, have enabled the study of chromatin states from very limited starting materials. In this chapter, we describe procedures for generating CUT&Tag libraries to profile histone modifications and histone variants in early-developing zebrafish embryos.

Animals↗

PubMed2026

Relaxin-2: Shaping the Proteomic Landscape of Skeletal Muscle Physiology, Glucose Trafficking, and Mitochondrial Function in Rat.

Relaxin-2 is a hormone with robust beneficial effects on the heart and blood vessels and potential as a therapy for cardiovascular (CV) disease. Considering the interorgan communication between skeletal muscle and heart, and the relation between muscle quality/composition and CV events, we hypothesize that relaxin-2 may regulate skeletal muscle physiology and metabolism. We aim to evaluate the impact of relaxin-2 on the proteome of skeletal muscle from healthy Sprague-Dawley rats. Animals were treated with 0.4 mg/kg/day of serelaxin (recombinant form of human relaxin-2) or vehicle (PBS) for 2 weeks employing subcutaneous osmotic minipumps. Skeletal muscle protein identification and quantification were performed by LC-MS/MS using a Data-Independent Acquisition (DIA)-Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH) method. SWATH/MS quantitative analysis identified that relaxin-2 significantly decreased 95 proteins and significantly increased 32 proteins in rat skeletal muscle when compared to control rats. From these, 34 proteins were associated with muscle function, myogenesis, muscle differentiation and/or regeneration, 20 are mitochondrial proteins (six from the complexes of the electron transport chain), and 10 proteins participate in glucose metabolism. Qualitative data-dependent workflow analysis identified 35 proteins exclusive to the skeletal muscle of the relaxin-2-treated group: eight proteins related to processes of skeletal muscle function (size, ion homeostasis or organization of caveolae structures and cytoskeleton) and myogenesis, and two proteins involved in muscle differentiation. Our work highlighted for the first time the role of relaxin-2 in crucial processes of muscle physiology and energetic metabolism, which could influence several processes involved in myopathy and CV.

Animals↗